系统综述:难治性IBD患者在接受先进疗法随机对照试验中的纳入情况
该系统综述回顾了179项溃疡性结肠炎(UC)和克罗恩病(CD)先进疗法随机对照试验(RCT),共54,258例患者,评估难治性IBD(DTT-IBD)患者的纳入与代表性。结果显示仅少数RCT纳入DTT-IBD患者,且多数试验中DTT-IBD仅占少数,缺乏亚组特异性疗效数据。
要点
- 仅16.1%的UC试验和10.5%的CD试验纳入DTT-IBD患者(暴露于≥2种作用机制药物)。
- 在报告患者水平数据的试验中,DTT-UC占16.2%,DTT-CD占22.4%。
- 除一项仅纳入DTT-UC的小型试验外,无DTT-IBD亚组疗效数据。
核心结论
- 极少数先进疗法RCT纳入DTT-IBD患者,且多数试验中DTT-IBD仅占少数人群,缺乏亚组特异性数据。
研究设计与样本
- 系统综述纳入179项UC和CD先进疗法RCT(UC 93项,CD 86项),共54,258例患者。
- DTT-IBD定义为尽管暴露于≥2种不同作用机制的先进疗法仍存在活动性疾病。
主要发现
- UC中72%(67/93)的研究纳入有先进疗法暴露史的患者,16.1%(15/93)纳入暴露于≥2种作用机制药物的患者。
- 在10项报告患者水平数据的UC试验中,DTT-UC占16.2%(814/5019)。
- CD中73.3%(63/86)的RCT纳入有先进疗法暴露史的患者,10.5%(9/86)报告了因暴露于多类先进疗法所致的DTT-CD患者。
- 多失败DTT-CD患者占报告研究人群的22.4%(773/3455)。
- 除一项仅纳入DTT-UC的小型试验外,未报告DTT-IBD的亚组特异性疗效结局。
临床怎么用
- 临床医生应知晓当前先进疗法RCT对DTT-IBD患者的代表性不足,试验结果外推至DTT-IBD人群需谨慎。
局限性
- 仅少数试验报告患者水平数据或DTT-IBD亚组数据,限制了对DTT-IBD疗效的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Criteria to define difficult-to-treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT-IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined. AIMS: To explore inclusion and representation of patients with DTT-IBD in RCTs. METHODS: We reviewed RCTs of advanced therapies (ATs) in ulcerative colitis (UC) and Crohn's disease (CD). DTT-IBD was defined as active disease despite exposure to ATs with ≥ 2 different mechanisms of action. Secondary analyses assessed eligibility and participation of patients exposed to ≥ 1 or ≥ 2 ATs irrespective of mechanism of action, and in CD only, active disease after ≥ 2 intestinal resections and fistulizing disease. RESULTS: We included 179 RCTs, 93 in UC and 86 in CD, comprising 54,258 patients. In UC, 72% (67/93) of studies included patients with prior exposure to ATs and 16.1% (15/93) included participants exposed to agents with ≥ 2 mechanisms of action (DTT); among the 10 trials reporting patient-level data, DTT-UC accounted for 16.2% (814/5019). In CD, 73.3% (63/86) of RCTs included patients with prior exposure to ATs, and 10.5% (9/86) reported patients with DTT-CD due to exposure to multiple classes of ATs. Patients with multifailure DTT-CD accounted for 22.4% (773/3455) of the reported study populations. Subgroup-specific efficacy outcomes for DTT-IBD were not reported, except for one small trial that enrolled only DTT-UC. CONCLUSIONS: Few RCTs of advanced medications include patients with DTT-IBD. In most trials, participants with DTT-IBD represent a minority of the study population, and subgroup-specific data are lacking.
引用
- Parigi TL, Solitano V, Mekonnen HD, et al. Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies. Aliment Pharmacol Ther. 2026. PMID: 42820390. doi:10.1111/apt.70998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。